Abstract
It is generally accepted that nifedipine and nicardipine, dihydropyridine (DHP) calcium antagonists (Ca-antagonists), are less cardiodepressant that verapamil and diltiazem, non-dihydropyridine (non-DHP) Ca-antagonists, in therapeutic doses used in the treatment of angina pectoris and/or hypertension. Such a property of nifedipine is indeed one of its advantages over the two non-DHP Ca-antagonists. However, owing to this property nifedipine tends to produce reflex tachycardia which is thought to be one of its undesirable effects [1]. Among new DHP Ca-antagonists developed recently PY 108–068 [2] and PN 200-110 [3] have been claimed less likely to produce reflex tachycardia. Thus, the question arises whether some of DHP Ca-antagonists produced by some modifications of the chemical structure of nifedipine possess a low separation between the vasodilator and the cardiac effects as do verapamil and diltiazem. The present article first treats this question and afterwards discusses mechanisms underlying a high separation between the vasodilator and the cardiac effects in DHP Ca-antagonists. To settle the first question the article treats seven DHP Ca-antagonists, i.e., nifedipine, nicardipine, nimodipine [4, 5], nisoldipine [6], nitrendipine [7, 8], PY 108–068 [2] and PN 200-110 [3] and three non-DHP Ca-antagonists, i.e., verapamil, diltiazem and KB-944 [9, 10].
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Ebner F (1975) In: Lochner W, Braasch W, Kroneberg G (eds) 2nd International Adalat Symposium. New therapy of ischemic heart disease. Springer, Berlin Heidelberg New York, p 348.
Hof RP, Hof A, Neumann P (1982) J Cardiovasc Pharmacol 4:352.
Hof RP, Hof A, Scholtysik G, Menninger K (1984) J Cardiovasc Pharmacol 6:407.
Kazda S, Hoffmeister F (1979) Naunyn-Schmiedeberg’s Arch Pharmacol 307:R43.
Kazda S, Garthoff B, Krause HP, Schloßmann K (1982) Arzneim-Forsch 32:331.
Kazda S, Garthoff H, Meyer H, Schloßmann K, Stoepel K, Towart R, Vater W, Wehinger E (1980) Arzneim-Forsch 30:2144.
Meyer H, Bossert F, Wehinger E, Stoepel K, Vater W (1981) Arzneim-Forsch 31:407.
Knorr A, Stoepel K (1981) Arzneim-Forsch 31:2062.
Morita T, Yoshino K, Kanazawa T, Ito K, Nose T (1982) Arzneim-Forsch 32:1037.
Morita T, Kanazawa T, Ito K, Nose T (1982) Arzneim-Forsch 32:1043.
Endoh M, Hashimoto K (1970) Am J Physiol 218:1459.
Himori N, Ono H, Taira N (1976) Jpn J Pharmacol 26:427.
Taira N, Kawada M, Satoh K (1983) J Cardiovasc Pharmacol 5:349.
Satoh K, Yanagisawa T, Taira N (1981) Clin Exp Pharmacol Physiol 7:249.
Satoh K, Kawada M, Wada Y, Taira N (1984) Arzneim-Forsch 34:563.
Takahashi K, Taira N (to be published) Arzneim-Forsch.
Satoh K, Wada Y, Taira N (1986) Arzneim-Forsch.
Wada Y, Satoh K, Taira N (1984) J Cardiovasc Pharmacol 6:881.
Wada Y, Satoh K, Taira N (1985) J Cardiovasc Pharmacol 7:190.
Endoh M, Kimura T, Hashimoto H (1974) Jpn J Pharmacol 24:771.
Kubota K, Hashimoto K (1973) Naunyn-Schmiedeberg’s Arch Pharmacol 278:135.
Hashimoto K, Iijima T, Hashimoto K, Taira N (1972) Tohoku J Exp Med 107:263.
Ono H, Himori N, Taira N (1977) Tohoku J Exp Med 121:383.
Narimatsu A, Taira N (1976) Naunyn-Schmiedeberg’s Arch Pharmacol 294:169.
Endoh M, Yanagisawa T, Taira N (1978) Naunyn-Schmiedeberg’s Arch Pharmacol 302:235.
Taira N (1979) In: Bing RJ (ed) New drug therapy with a calcium antagonist. Diltiazem Hakone Symposium 1978. Excerpta Medica, Amsterdam Princeton, p 91.
Iijima T, Yanagisawa T, Taira N (1984) J Moll Cell Cardiol 16:1173.
Sakamoto N, Terai M, Takenaka T, Maeno H (1978) Biochem Pharmacol 27:1269.
Nishikori K, Takenaka T, Maeno H (1981) Jpn J Pharmacol 31:701.
Norman JA, Ansell J, Phillips MA (1983) Eur J Pharmacol 93:107.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1985 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Taira, N. (1985). Differences Between Dihydropyridine and Non-Dihydropyridine Calcium Antagonists in Inotropic, Chronotropic, Dromotropic and Vascular Effects: Differences in Underlying Mechanism. In: Fleckenstein, A., Van Breemen, C., Gross, R., Hoffmeister, F. (eds) Cardiovascular Effects of Dihydropyridine-Type Calcium Antagonists and Agonists. Bayer-Symposium, vol 9. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-70499-4_24
Download citation
DOI: https://doi.org/10.1007/978-3-642-70499-4_24
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-70501-4
Online ISBN: 978-3-642-70499-4
eBook Packages: Springer Book Archive